Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 8/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MGAM | O43451 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SI | P14410 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.63 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31331777 | 0.82 | MCL1 (0.70) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL11227296 | 0.81 | MCL1 (0.68) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL7358800 | 0.80 | MCL1 (0.67) | MCL1MAOBGAAKDM4EALDH1A1 | |
| 4-Methyldaphnetin SCHEMBL1065373 | 0.78 | MCL1 (1.00) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL4187220 | 0.78 | MAOB (1.00) | MCL1MAOBGAAKDM4EALDH1A1 | |
| 4-Methyldaphnetin SCHEMBL29671915 | 0.78 | MCL1 (1.00) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL4929327 | 0.78 | PIM1 (0.64) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL9996019 | 0.77 | DYRK1A (1.00) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL27860821 | 0.77 | MAOB (0.69) | MCL1MAOBGAAKDM4EALDH1A1 | |
| SCHEMBL9643035 | 0.76 | MAOB (0.62) | MCL1MAOBGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-7772334-B2 | Crosslinker of reactive functional groups and nonionic metal coordinating structure-containing alkyl or aromatic compound | BASF COATINGS GMBH (DE) | 2010-08-10 | — | — | US | claimed |
| US-7759436-B2 | Film-former of resin with nonionic metal coordinating structure and crosslinker-reactive group | BASF COATINGS GMBH (DE) | 2010-07-20 | — | — | US | claimed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | claimed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | claimed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004002953-A2 | LACTONE COMPOUNDS, FOR USE AS ANTIOXIDANT AGENTS IN PHARMACEUTICAL, COSMETIC OR FOOD COMPOSITIONS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-01-08 | — | — | WO | disclosed |
| EP-0157384-B1 | Substrates for hydrolases, process for their preparation and their use | BIOMED LABORDIAGNOSTIK GMBH (DE) | 1995-01-18 | — | — | EP | disclosed |
| US-4716222-A | CHROMOGENS, SPECTROPHOTOMETRY | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-12-29 | — | — | US | disclosed |
| EP-0157384-A2 | Substrates for hydrolases, process for their preparation and their use | Biomed Labordiagnostik GmbH (DE) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MCL1 2566/4885MAOB 2481/4885GAA 3100/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | MCL1 776/4885MAOB 4393/4885GAA 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.